• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清富含亮氨酸α-2 糖蛋白水平预测克罗恩病临床缓解患者肠道病变活动性超声表现。

Serum leucine-rich alpha-2 glycoprotein levels for predicting active ultrasonographic findings in intestinal lesions of patients with Crohn's disease in clinical remission.

机构信息

Sapporo IBD Clinic, Sapporo, Japan.

Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.

出版信息

Medicine (Baltimore). 2023 Aug 11;102(32):e34628. doi: 10.1097/MD.0000000000034628.

DOI:10.1097/MD.0000000000034628
PMID:37565885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10419375/
Abstract

This study aimed to investigate the cutoff value of leucine-rich alpha-2 glycoprotein (LRG) in predicting active intestinal ultrasonography (IUS) findings in patients with Crohn's disease (CD) in clinical remission. Data were retrospectively collected from patients with CD evaluated using LRG and undergoing IUS from September 2020 to August 2022. Patients with a Harvey-Bradshaw Index of ≤4 were included and those who underwent intestinal resection were excluded. Bowel wall thickness and stratification and blood flow signal using superb microvascular imaging (SMI) were used to assess ultrasonography findings. SMI signals were categorized into 4 grades following the Limberg score. Receiver operating characteristic curves were constructed and the area under the curve was calculated to determine the LRG cutoff values for predicting active IUS findings and were compared with those of C-reactive protein. This study included 213 patients. The LRG cutoff values to predict active bowel wall thickness, loss of bowel wall stratification, and SMI of ≥1, ≥2, and 3 were 14.6 μg/mL, 14.6 μg/mL, 14.6 μg/mL, 14.6 μg/mL, and 16.9 μg/mL, respectively, with significantly higher areas under the curve in SMI of ≥1 and 3 than in C-reactive protein. The best LRG cutoff value for predicting active IUS findings was 14.6 μg/mL in patients with CD in clinical remission, suggesting that LRG is better than C-reactive protein for detecting active IUS findings in CD.

摘要

本研究旨在探讨富含亮氨酸α-2 糖蛋白(LRG)在预测处于临床缓解期的克罗恩病(CD)患者的活性肠道超声(IUS)结果中的截断值。研究数据是从 2020 年 9 月至 2022 年 8 月期间接受 LRG 评估并进行 IUS 的 CD 患者中回顾性收集的。纳入 Harvey-Bradshaw 指数≤4 的患者,并排除接受肠道切除术的患者。采用 superb microvascular imaging(SMI)评估肠壁厚度和分层以及血流信号。根据 Limberg 评分,SMI 信号分为 4 个等级。构建受试者工作特征曲线并计算曲线下面积,以确定预测活性 IUS 结果的 LRG 截断值,并与 C-反应蛋白进行比较。本研究纳入了 213 例患者。预测活性肠壁厚度、肠壁分层丧失和 SMI≥1、≥2 和 3 的 LRG 截断值分别为 14.6μg/mL、14.6μg/mL、14.6μg/mL、14.6μg/mL 和 16.9μg/mL,SMI≥1 和 3 的曲线下面积明显高于 C-反应蛋白。在处于临床缓解期的 CD 患者中,预测活性 IUS 结果的最佳 LRG 截断值为 14.6μg/mL,提示 LRG 比 C-反应蛋白更适合检测 CD 的活性 IUS 结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/e74f2aaa1d66/medi-102-e34628-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/43afb653434b/medi-102-e34628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/c784a24c5996/medi-102-e34628-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/0c836393b285/medi-102-e34628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/c7076afe564f/medi-102-e34628-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/664e069eea00/medi-102-e34628-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/e74f2aaa1d66/medi-102-e34628-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/43afb653434b/medi-102-e34628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/c784a24c5996/medi-102-e34628-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/0c836393b285/medi-102-e34628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/c7076afe564f/medi-102-e34628-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/664e069eea00/medi-102-e34628-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ef/10419375/e74f2aaa1d66/medi-102-e34628-g006.jpg

相似文献

1
Serum leucine-rich alpha-2 glycoprotein levels for predicting active ultrasonographic findings in intestinal lesions of patients with Crohn's disease in clinical remission.血清富含亮氨酸α-2 糖蛋白水平预测克罗恩病临床缓解患者肠道病变活动性超声表现。
Medicine (Baltimore). 2023 Aug 11;102(32):e34628. doi: 10.1097/MD.0000000000034628.
2
Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.血清富含亮氨酸的α-2 糖蛋白和钙卫蛋白在炎症性肠病患儿中的变化:日本多中心研究。
J Gastroenterol Hepatol. 2023 Jul;38(7):1131-1139. doi: 10.1111/jgh.16166. Epub 2023 Mar 16.
3
Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.血清富含亮氨酸α-2 糖蛋白可作为预测克罗恩病内镜缓解的指标。
J Gastroenterol Hepatol. 2022 Sep;37(9):1741-1748. doi: 10.1111/jgh.15907. Epub 2022 Jun 10.
4
Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease.血清富含亮氨酸的α-2 糖蛋白在评估克罗恩病内镜疾病活动中的准确性。
Inflamm Bowel Dis. 2023 Feb 1;29(2):245-253. doi: 10.1093/ibd/izac076.
5
Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn's Disease: Is There Any Difference between Small Intestine and Colonic Lesions?血清富含亮氨酸的α2糖蛋白在克罗恩病中的作用:小肠病变与结肠病变之间有差异吗?
Crohns Colitis 360. 2023 May 23;5(3):otad028. doi: 10.1093/crocol/otad028. eCollection 2023 Jul.
6
Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.应用等离子体替代血清检测富含亮氨酸α2-糖蛋白作为炎症性肠病的生物标志物。
PLoS One. 2023 Jun 23;18(6):e0286415. doi: 10.1371/journal.pone.0286415. eCollection 2023.
7
Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.富含亮氨酸α-2 糖蛋白在炎症性肠病中监测疾病活动和肠狭窄。
Tohoku J Exp Med. 2022 Jul 16;257(4):301-308. doi: 10.1620/tjem.2022.J042. Epub 2022 May 20.
8
Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn's disease small bowel lesion in capsule endoscopy.血清富含亮氨酸的α-2糖蛋白在预测克罗恩病小肠病变胶囊内镜检查结果中的效能
Intest Res. 2024 Oct;22(4):464-472. doi: 10.5217/ir.2023.00139. Epub 2024 May 7.
9
Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.富含亮氨酸的α-2 糖蛋白是评估炎症性肠病临床和内镜疾病活动的可靠血清生物标志物。
Inflamm Bowel Dis. 2023 Sep 1;29(9):1399-1408. doi: 10.1093/ibd/izac230.
10
Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission.富含亮氨酸的α-2糖蛋白有助于预测克罗恩病患者在生物缓解期的临床复发情况。
Intest Res. 2025 Apr;23(2):170-181. doi: 10.5217/ir.2024.00042. Epub 2024 Aug 19.

引用本文的文献

1
Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn's disease.富含亮氨酸的α-2糖蛋白作为一种比C反应蛋白更优的生物标志物,用于检测克罗恩病中的小肠病变。
World J Gastrointest Endosc. 2025 Feb 16;17(2):100793. doi: 10.4253/wjge.v17.i2.100793.
2
Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn's disease: a single-centre, cross-sectional study.富含亮氨酸的α-2糖蛋白联合C反应蛋白预测克罗恩病的内镜活动度:一项单中心横断面研究
Ann Med. 2025 Dec;57(1):2453083. doi: 10.1080/07853890.2025.2453083. Epub 2025 Jan 17.
3
Serum Leucine-Rich α2 Glycoprotein Could Be a Useful Biomarker to Differentiate Patients with Normal Colonic Mucosa from Those with Inflammatory Bowel Disease or Other Forms of Colitis.
血清富含亮氨酸的α2糖蛋白可能是区分结肠黏膜正常患者与炎症性肠病或其他形式结肠炎患者的有用生物标志物。
J Clin Med. 2024 May 17;13(10):2957. doi: 10.3390/jcm13102957.